ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2718

The UCLA Gastrointestinal Tract Questionnaire (GIT)2.0 and GI Visual Analogue Scale(GI-VAS) Reflect Different Aspects of GI Involvement in Systemic Sclerosis

Yossra Suliman1,2, Yasser Shaweesh3, Suzanne Kafaja4,5,6, Lewei Duan7 and Daniel E. Furst8, 1Division of Rheumatology, Department of Medicine., David Geffen School of Medicine, University of California Los Angeles,, Los Angeles, CA, 2Rheumatology and Rehabilitation department, Faculty of Medicine, Assiut university, Assiut, Egypt, 3Division of Rheumatology, Department of Medicine., David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, 4Rheumatology, University of California Los Angeles, Los Angeles, CA, 5Medicine, University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 6David Geffen School of Medicine, UCLA, Los Angeles, CA, 7David Geffen School of Medicine, University of California School of Medicine, Los Angeles, CA, 8University of California at Los Angeles, Los Angeles, CA

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: gastrointestinal complications, measure, patient outcomes and systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's - Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response

Session Type: Abstract Submissions (ACR)

Background/Purpose

UCLA GIT2.0 is a validated measure for assessing the severity of gastrointestinal involvement in systemic sclerosis patients (SSc) patients; GI VAS is also a widely used measure of GI effect in patients as a component of SSc health assessment questionnaire (SHAQ). GIT2.0 includes 34 questions in 7 domains (reflux, distension, soilage, diarrhea, social function, emotional wellbeing and constipation). GI VAS is a 100 mm VAS that asks the patient; how much GI symptoms interfere with patient function. Both are measures of present state.

Objectives  

1) Is there a correlation between GI-VAS and total GIT2.0?

2) Is a correlation between GI-VAS and GIT2.0 domains?

3) Does total GIT2.0 or GI-VAS predict patient global.

Methods

We extracted baseline data in 98 consecutive SSc patients, with respect to: age, sex, SSc subtype, disease duration, HAQ-DI, VAS for: pain, raynaud’s, ulcer, breathing, GIT2.0 domains and patient global.

Analysis:-Correlation between GI VAS and GIT 2.0 (total and individual domains) by Pearson correlation Coefficient. Univariable linear regression using patient global as dependent variable against total GIT2.0 or GI-VAS as separate independent elements. Independent variables were: SSc subtype, age, gender, disease duration, VAS for: raynaulds, finger ulcers and breathing in each model.

Results

Of total 98 patients available for analysis, 84 were females, 59 were diffuse subtype, mean age 54.6 (SD 14), mean disease duration 9.6 years (7.6), total GIT2.0 mean0.51 (0.49) – moderate, GI-VAS mean2.34 (2.77)- mild, HAQ-DI mean 0.98 (0.76) and patient global mean 3.77(2.69). Correlation between GI VAS and GIT2.0 (total and individual domains) are listed in table1. Even though the correlation between GIT2.0 and GIT VAS is (r=0.6) and weighted kappa is 0.59 –moderate, thirty four percent of the patients showed  disagreement between the two measures by at least 1 category (total of four categories). Linear regression analysis demonstrated that GIT2.0 and GI-VAS were independent predictors of patient global as were VAS for breathing and ulcer (p<0.007). Adjusted r squared for GIT2.0 was 0.49and for GI-VAS was0.51.

Table1. Correlation between GI VAS and GIT2.0 (total and individual domains)

 

GIT2.0

Reflux

Distension

Soilage

Diarrhea

Constipation

Social function

Emotional wellbeing

GI VAS

0.61

0.56

0.54

0.32

0.26

0.33

0.58

0.49

 

 

Conclusion

GIT2.0 and GI VAS reflect GIT involvement. Each separately is an independent predictor of patient global. They disagree sufficiently frequently that they may reflect different aspects of GI involvement and might be considered separately in clinical GI evaluation of SSc patients.

 

 


Disclosure:

Y. Suliman,
None;

Y. Shaweesh,
None;

S. Kafaja,
None;

L. Duan,
None;

D. E. Furst,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-ucla-gastrointestinal-tract-questionnaire-git2-0-and-gi-visual-analogue-scalegi-vas-reflect-different-aspects-of-gi-involvement-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology